Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

Synergy Pharmaceuticals logo

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.03
52-Week Range
N/A
Volume
N/A
Average Volume
6.08 million shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SGYP Stock News Headlines

Jose Solorio
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Synergy Pharmaceuticals Inc Unit (SGYPU)
Different resistors
Mains cables
See More Headlines

SGYP Stock Analysis - Frequently Asked Questions

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Westmoreland Coal (WLB), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/08/2018
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGYP
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-224,330,000.00
Net Margins
-332.11%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.82 million
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$7.44 million
Optionable
Optionable
Beta
4.94
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SGYP) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners